In a previous study, we synthesized a novel inhibitor of ceramide kinase, K1. In this study, we determined that inhibition by K1 is non-competitive and that four intact six-membered rings are important to the inhibitory activity. Furthermore, we identified an effective in vivo concentration for K1, at which it did not influence any cellular lipid synthesis other than that of ceramide 1-phosphate (C1P) using RBL-2H3 cells, and found that K1 suppressed the activation of mast cells.
Activation of mast cells plays a pivotal role in allergic and inflammatory responses such as asthma and anaphylaxis. It is initiated by an aggregation of IgE receptors (Fc"R) and culminates in degranulation, the exocytosis of granule contents, including inflammatory cytokines. Thus the regulation of degranulation is a potential target for anti-allergic therapeutics.
Sphingolipids are ubiquitous components of the eukaryotic plasma membrane. Ceramide (Cer), the precursor of all sphingolipids, also functions as a second messenger in a variety of cellular events, including apoptosis and differentiation. 1) Because of the importance of Cer, enzymes involved in its metabolism have also become a focus of recent attention. In a previous study, we found that ceramide kinase (CerK), the enzyme responsible for phosphorylating Cer, is involved in the activation of mast cells. 2) In the next study, we also synthesized a novel inhibitor of CerK, named K1, that is a cyclic isomer of a known sphingosine kinase 1 (SPHK1) inhibitor, F12509A.
3) Since CerK is involved in mast cell activation, K1 might be a candidate for therapeutic agent for allergies, but, the mechanism by which K1 inhibits CerK and its study on cellular lipids have not yet been fully characterized. In this report, we investigated the structure-activity relationships of K1 and its analogs, and determined its means of inhibition by kinetic studies. In addition, we examined the effect of K1 on the activation of bone marrow-derived mast cells.
First we synthesized the four K1 analogs (Fig. 1A ), using techniques described previously. 4) KD and KB are enantiomers of K1 and F12509A respectively. Another, K2, is a cyclohexane derivative that possesses a benzoquinone, and the fourth, KC carries an additional hydrogen at the double bound in the methylene position of F12509A. We examined the inhibitory effect of these compounds on CerK activity in vitro using techniques described previously. 5) K1 and KD strongly inhibited CerK activity, whereas the other compounds showed only weak inhibition (Fig. 1B) . These results were then transformed to a Scatchard plot ( Fig. 2A ) according to the method described previously.
6) The intercepting point on the X-axis in each plot give the inverse value of K i . The plots indicated K i values for K1 and KD of 2.2 mM and 3.3 mM respectively, whereas that for KC was 452 mM.
The K i value of F12509A against SPHK1 has been reported to be 4.0 mM, 3) and thus in comparison, the K i values of K1 and KD sre low enough for these inhibitors to be used as experimental reagents. Furthermore, the strong inhibitory activities of K1 and KD as compared to the other compounds indicate that their inhibition of CerK requires the four six-membered rings found only in K1 and KD. Based on this information, it is reasonable to conclude that further chemical modification might produce a more potent inhibitor. It is also interesting that there was not much difference between the activities of K1 and KD, which are enantiomers. This result indicate that CerK dose not recognize the absolute configuration of these compounds. The next question, then, is how K1 and KD inhibit CerK.
y To whom correspondence should be addressed. Fax: +81-11-706-4986; E-mail: yigarash@pharm.hokudai.ac.jp Abbreviations: Cer, ceramide; SM, sphingomyelin; CerK, ceramide kinase; C1P, ceramide 1-phosphate; PS, phosphatidyl serine; PE, phosphatidyl ethanolamine; BMMC, bone marrow-derived mast cells A, The structures of K1, F12509A, and related analogs KD, KC, KB, and K2. B, The inhibition of CerK activity by K1, F12509A, KD, KC, KB, and K2. HEK293 cells were transfected with pcDNA-FLAG hCERK encoding FLAG-tagged human CERK, and cultured for 24 h. The cells were lysed in buffer (10 mM HEPES, pH 7.4, 2 mM EGTA, 40 mM KCl, and CompleteÔ protease inhibitor mixture, Roche, Germany), and CerK was purified from lysates by immunoprecipitaition with anti-FLAG M2 beads (Sigma). The precipitated enzymes were suspended in CerK assay buffer (40 mM HEPES, pH 7.5, 100 mM KCl, 3 mM CaCl 2 , 1 mM DTT, and CompleteÔ protease inhibitor mixture), and adjusted to a protein concentration of 7.2 mg/ml. An aliquot of enzyme (70 ml) was incubated for 10 min with a sample of each compound (5 ml) at the indicated concentrations. Enzyme reactions were initiated by the addition of 1 ml of [-32 P]ATP (10 nM, 2 mCi/ml, Institute of Isotope Co., Ltd.), 9 ml of 240 nM cold ATP, and 20 ml of mixed micelles (5 mM cardiolipin, 7.5% -octylglucoside, 1 mM diethylenetriaminepentaacetic acid, and 200 mM ceramide, C16:0, d18:1, Sigma). After 30 min incubation at 30 C, [ 32 P]C1P was extracted from each sample and quantified as described previously. 5) CerK activity without any compounds (40 pmol/min/mg protein) was expressed as 100. To investigate the kinetics of the inhibition by K1 and KD, Lineweaver-Burk plot analysis was performed. As shown in Fig. 2B and C, increasing the amount of K1 or KD decreased the V max value of CerK, whereas the K m values did not change. Furthermore, the three lines intercepted on the X-axis of the plot, and these patterns of inhibition are typical of noncompetitive inhibition. CerK activity is known to be regulated by several domains within the protein, in addition to the substrate recognition domain. For example, at its N-terminus, CerK has a pleckstrin-homology (PH) domain that is known to be important for its activity. Mutations in the PH-domain cause a dramatic decrease in CerK activity, but have no effect on substrate affinity or K m value. 7) CerK also has a Ca 2þ /CaM binding site, which is important for their Ca 2þ -dependent activation. 8) K1 and KD might inhibit the activity of these regions and thereby inhibit CerK activity in a non-competitive manner.
To confirm the specify of K1 on CerK inhibition, we proceeded to examine its effect on cellular lipids. Serine is the precursor of all sphingolipids and of phosphatidyl serine (PS), which is converted to phosphatidyl ethanolamine (PE) by PS decarboxylase. Hence, we used [
14 C] Serine incorporation to determine the cellular contents of sphingolipids PS and PE. K1 did not alter gross lipids synthesis when used at a concentration below 50 mM (Fig. 3A) . We also examined cellular C1P synthesis with [
32 P]ATP in RBL-2H3 cells. A concentrations above 20 mM, K1 efficiently reduced C1P synthesis (Fig. 3B) . Hence, we concluded that concentration range of 10 mM to 50 mM would be appropriate for use in cell research. We also investigated the effect of K1 on mast cell activation using mouse bone marrow-derived mast cells (BMMC), and found that K1 suppressed degranulation in a dose-dependent manner (Fig. 3C) . It suppressed C1P formation at concentrations that did not alter other lipid metabolism in RBL-2H3 cells (Fig. 3A,  B) , which implies that the inhibition of degranulation by K1 in BMMC occurs by inhibiting CerK and consequently C1P formation.
Our data suggest that K1 and other CerK inhibitors might be candidates for therapeutic agents capable of suppressing mast cell activation associated with allergic responses. In this study, we found a structure-activity relationship for K1 using K1 derivatives. Based on this information, advanced chemical modification might produce potential CerK inhibitors. In a future study, we will examine the anti-allergy effects of CerK inhibitors by in vivo animal experiments. 2) The data represent the mean AE SD of three determinations. Ã p < 0:01 for treatment of K1 versus no treatment of K1. C, Effect of K1 on degranulation of mast cells. BMMC were prepared as described elsewhere.
9) The cells were preincubated with the indicated concentrations of K1, then stimulated with 0.2 mM calcium ionophore A23187. Degranulations was assayed as described previously.
2) The data represent the mean AE SD of three determinations.
Ã p < 0:01 for treatment of K1 versus no treatment of K1.
